Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin in adults with primary IgA nephropathy
ChiCTR2300067263Phase 4Recruiting
- Sponsor
- Army Specialized Medical Center
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of dapagliflozin in IgA nephropathy (IgAN) (2 arms), sponsored by Army Specialized Medical Center. Primary endpoints: 24-hour urinary protein quantification, Rate of change of urinary protein and 1 more. Started Jan 2023; status: recruiting.
02
Drugs
dapagliflozin
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on ChiCTR2300067263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300067263.